Physician profile
Rian Jonathan Rowles
NPI 1447398870
$15,443.34
in general payments reported to CMS, 2019-2025
28 companies · $3,553 in 2025
The $3,553 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $1,198 · 2021: $1,719 · 2022: $1,662 · 2023: $3,372 · 2024: $2,696 · 2025: $3,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,509 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,509.09 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,965.75 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $2,118.34 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,665.64 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,123.46 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,050.26 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,040.93 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $852.31 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $614.33 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $590.37 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Jazz Pharmaceuticals INC. | $576.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $531.23 | 2019-2025 | Trintellix |
| Alkermes, INC. | $510.45 | 2020-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $417.18 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $308.81 | 2022-2025 | Azstarys, Adlarity |
| Idorsia Pharmaceuticals US INC | $251.85 | 2022-2025 | Quviviq, Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $181.39 | 2025 | Cobenfy |
| Tris Pharma INC | $116.63 | 2022-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $107.40 | 2021-2023 | Loreev Xr |
| Alpha Cognition USA, INC. | $88.40 | 2025 | Zunveyl |
| Acadia Pharmaceuticals INC | $88.04 | 2019-2020 | |
| Eisai INC. | $73.81 | 2020-2021 | |
| Shire North American Group INC | $55.03 | 2019 | |
| Bausch Health US, LLC | $46.87 | 2022-2023 | Wellbutrin, Aplenzin |
| Sunovion Pharmaceuticals INC. | $17.48 | 2019 | |
| Noven Therapeutics, LLC | $16.51 | 2024 | Secuado, Xelstrym |
| Adlon Therapeutics L.P. | $14.72 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.08 | 2023 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $6.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rian Rowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.